{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:35:17Z","timestamp":1774280117056,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The molecular non-genetic changes of resistance to sotorasib are currently uncertain. The aim of this study was to generate a sotorasib-resistant cell line via selective pressure and systematically examine the molecular and phenotypic alterations caused by resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Mutant NCI-H358 (KRAS<jats:sup>G12C<\/jats:sup>) were exposed to incremental doses (2\u2013512 nM) of sotorasib. Then, resistant clones were separated by single-cell sorting. Proliferation was analyzed in real-time by xCELLigence; protein profiles were quantified by protein arrays; and mRNA expression profile was measured using the PanCancer Pathways panel by NanoString. <jats:italic>In silico<\/jats:italic> analyses were conducted from a database comprising patient-derived xenograft (PDX) models and cell lines resistant to sotorasib. AKT and p38. The synergistic effect of combining AKT, p38, and EGFR inhibitors was assessed using the SynergyFinder platform. Additionally, AKT and p38 genes were silenced using esiRNA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sotorasib-resistant H358-R cell line displayed markers of the mesenchymal-epithelial transition and loss of cell adhesion. Were identified 30 overexpressed genes in the resistance model, implicating in signaling pathways that leads to AKT activation and heightened protein expression levels of phosphorylated AKT and p38. To identify potential therapeutic strategies for overcoming sotorasib resistance, we investigated the combination of AKT and p38 inhibitors. Notably, combined inhibition of AKT (MK2206) and p38 (adezmapimod) restored sensitivity to sotorasib in resistant cell lines, as did silencing AKT expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings underscore the importance of adaptive mechanisms in sotorasib resistance in NSCLC cells contributing by EMT activation and demonstrates synergic combination with AKT and p38 inhibitors to restore sotorasib sensitivity in KRAS<jats:sup>G12C<\/jats:sup> cells.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmolb.2025.1537523","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:10:54Z","timestamp":1738213854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling"],"prefix":"10.3389","volume":"12","author":[{"given":"Raquel Arantes","family":"Megid","sequence":"first","affiliation":[]},{"given":"Guilherme Gomes","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Izabela Natalia Faria","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Ana Carolina","family":"Laus","sequence":"additional","affiliation":[]},{"given":"Let\u00edcia","family":"Ferro Leal","sequence":"additional","affiliation":[]},{"given":"Luciane","family":"Sussuchi da Silva","sequence":"additional","affiliation":[]},{"given":"Abu-Bakr Adetayo","family":"Ariwoola","sequence":"additional","affiliation":[]},{"given":"Josiane Mour\u00e3o","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[]},{"given":"Renato","family":"Jose da Silva-Oliveira","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets--update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res. Jan."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs. Sep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41416-022-02032-w","article-title":"PAK and PI3K pathway activation confers resistance to KRAS(G12C) inhibitor sotorasib","volume":"128","author":"Chan","year":"2023","journal-title":"Br. J. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nrm808","article-title":"Integration of calcium and Ras signalling","volume":"3","author":"Cullen","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms23147774","article-title":"Efficacy of combined use of everolimus and second-generation pan-EGRF inhibitors in KRAS mutant non-small cell lung cancer cell lines","volume":"14","author":"da Silva-Oliveira","year":"2022","journal-title":"Int. J. Mol. Sci. Jul"},{"key":"B10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/c5mb00101c","article-title":"The PI3K\/AKT\/mTOR interactive pathway","volume":"11","author":"Ersahin","year":"2015","journal-title":"Mol. Biosyst"},{"key":"B12","doi-asserted-by":"publisher","first-page":"118513","DOI":"10.1016\/j.lfs.2020.118513","article-title":"PI3K\/AKT\/mTOR signaling in gastric cancer: epigenetics and beyond","volume":"262","author":"Fattahi","year":"2020","journal-title":"Life Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11427-023-2499-2","article-title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K\/Akt\/mTOR pathway","volume":"67","author":"Ganesan","year":"2024","journal-title":"Sci. China Life Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/459508a","article-title":"A change of strategy in the war on cancer","volume":"459","author":"Gatenby","year":"2009","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e127552","DOI":"10.1172\/jci.insight.127552","article-title":"RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer","volume":"25","author":"Gbenedio","year":"2019","journal-title":"JCI Insight"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","article-title":"ShinyGO: a graphical gene-set enrichment tool for animals and plants","volume":"36","author":"Ge","year":"2020","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cells11010154","article-title":"Comprehensive molecular landscape of cetuximab resistance in head and neck cancer cell lines","volume":"11","author":"Gomes","year":"2022","journal-title":"Cells"},{"key":"B18","first-page":"2172","article-title":"The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines","volume":"63","author":"Grille","year":"2003","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/1541-7786.MCR-12-0558","article-title":"Molecular dissection of AKT activation in lung cancer cell lines","volume":"11","author":"Guo","year":"2013","journal-title":"Mol. Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1756-9966-28-28","article-title":"Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells","volume":"28","author":"Hong","year":"2009","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"B21","first-page":"1032","article-title":"Wnt2 promotes non-small cell lung cancer progression by activating WNT\/\u03b2-catenin pathway","volume":"5","author":"Huang","year":"2015","journal-title":"Am. J. cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12038-020-00045-2","article-title":"Assessment of telomerase as drug target in breast cancer","volume":"45","author":"Jaiswal","year":"2020","journal-title":"J. Biosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a G12C mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"90948","DOI":"10.18632\/oncotarget.18770","article-title":"PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer","volume":"31","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7443","DOI":"10.1038\/sj.onc.1209091","article-title":"Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase\/AKT pathways","volume":"24","author":"Larue","year":"2005","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2400160","DOI":"10.1002\/advs.202400160","article-title":"TBL2 promotes tumorigenesis via PRMT5\/WDR77-mediated AKT activation in breast cancer","volume":"11","author":"Lu","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00109-016-1382-7","article-title":"K-Ras protein as a drug target","volume":"94","author":"McCormick","year":"2016","journal-title":"J. Mol. Med. Berl. Mar."},{"key":"B29","doi-asserted-by":"publisher","first-page":"eade3816","DOI":"10.1126\/sciadv.ade3816","article-title":"Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer","volume":"13","author":"Mohanty","year":"2023","journal-title":"Sci. Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2009.04.030","article-title":"WNT\/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis","volume":"138","author":"Nguyen","year":"2009","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1004669","DOI":"10.3389\/fonc.2022.1004669","article-title":"Non-genetic adaptive resistance to KRAS(G12C) inhibition: EMT is not the only culprit","volume":"12","author":"Ning","year":"2022","journal-title":"Front. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41401-022-01015-0","article-title":"Targeting PI3K\u03b1 overcomes resistance to KRas(G12C) inhibitors mediated by activation of EGFR and\/or IGF1R","volume":"44","author":"Qi","year":"2023","journal-title":"Acta Pharmacol. Sin. May"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2174\/09298673113209990226","article-title":"In vitro and in vivo models for analysis of resistance to anticancer molecular therapies","volume":"21","author":"Rosa","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"B36","first-page":"4135","article-title":"p38 stabilizes Snail by suppressing DYRK2-mediated phosphorylation that is required for GSK3beta-betaTrCP-induced Snail degradation","volume":"15","author":"Ryu","year":"","journal-title":"Cancer Res. Aug"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1158\/0008-5472.CAN-19-0049","article-title":"p38 stabilizes Snail by suppressing DYRK2-mediated phosphorylation that is required for gsk3\u03b2-\u03b2TrCP-induced Snail degradation","volume":"79","author":"Ryu","year":"","journal-title":"Cancer Res. Aug 15"},{"key":"B38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1134\/s1990519x24700421","article-title":"esiRNA mediated silencing of HIF1A regulates migration, invasion, apoptosis, and proliferation of MDA-MB-231 cells","volume":"18","author":"Sharaf","year":"2024","journal-title":"Cell Tissue Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13402-016-0270-z","article-title":"Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker","volume":"39","author":"Silva-Oliveira","year":"2016","journal-title":"Cell. Oncol. Dordr. Neth."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1042\/BST0340858","article-title":"Regulation of Ras in lymphocytes: get a GRP","volume":"34","author":"Stone","year":"2006","journal-title":"Biochem. Soc. Trans. Nov."},{"key":"B42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.3892\/ol.2019.10009","article-title":"Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer","volume":"17","author":"Sunaga","year":"2019","journal-title":"Oncol. Lett. Mar."},{"key":"B44","first-page":"1545","article-title":"Vimentin regulates invasiveness and is a poor prognostic marker in non-small cell lung cancer","volume":"36","author":"Tadokoro","year":"2016","journal-title":"Anticancer Res. Apr"},{"key":"B45","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1172\/jci155523","article-title":"Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition","volume":"15","author":"Tsai","year":"2022","journal-title":"J. Clin. Invest"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/bioinformatics\/bts188","article-title":"NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data","volume":"28","author":"Waggott","year":"2012","journal-title":"Bioinformatics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3892\/mmr.2018.9279","article-title":"miR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt\/\u03b2-catenin pathway in non-small cell lung cancer","volume":"18","author":"Wang","year":"","journal-title":"Mol. Med. Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10549-018-4816-9","article-title":"Gene expression in triple-negative breast cancer in relation to survival","volume":"171","author":"Wang","year":"","journal-title":"Breast Cancer Res. Treat"},{"key":"B49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biocel.2017.01.005","article-title":"Cinnamaldehyde induces apoptosis and reverses epithelial-mesenchymal transition through inhibition of Wnt\/\u03b2-catenin pathway in non-small cell lung cancer","volume":"84","author":"Wu","year":"2017","journal-title":"Int. J. Biochem. and cell Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1083\/jcb.200201110","article-title":"Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis","volume":"157","author":"You","year":"2002","journal-title":"J. Cell Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.7150\/jca.18161","article-title":"Rac3 regulates cell invasion, migration and EMT in lung adenocarcinoma through p38 MAPK pathway","volume":"8","author":"Zhang","year":"2017","journal-title":"J. Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s11010-023-04839-4","article-title":"Phosphorylation of RasGRP1 by Shc3 prevents RasGRP1 degradation and contributes to Ras\/c-Jun activation in hepatocellular carcinoma","volume":"479","author":"Zhang","year":"2024","journal-title":"Mol. Cell. Biochem. Sep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1537523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:10:59Z","timestamp":1738213859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1537523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":53,"alternative-id":["10.3389\/fmolb.2025.1537523"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1537523","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"article-number":"1537523"}}